Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson’s Disease

Strong enrollment in Phase 3 trial demonstrates continued execution

Interim analysis expected in 2Q 2023

See more here